Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Soliton's Shares Went on a Roller Coaster Ride Today

By Todd Campbell - May 30, 2019 at 4:26PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company is riding high following FDA clearance for its tattoo removal medical device.

What happened

After securing Food and Drug Administration approval on May 28 for a device that may improve tattoo removal, shares of Soliton ( SOLY 0.75% ) climbed from $6 per share to over $29 per share on Wednesday. Shares spiked by another 22% earlier today before finishing 8% lower at 4 p.m. EDT. Here's what is causing this stock's eye-popping volatility.

So what

An estimated 70 million Americans have tattoos, and according to Soliton, over 60% of them would consider full or partial removal.

One with tattoos and one arm without tattoos give the thumb's up sign.

Image source: Getty Images.

Currently, tattoo removal is commonly done using lasers that break up ink into tiny particles that can be removed from the body naturally. But this process can take up to 10 visits at an out-of-pocket cost of $100 to $500 per visit, and its results often fall short.

In clinical trials, Soliton's Rapid Acoustic Pulse (RAP) device produced superior results when used alongside laser treatment versus laser treatment alone. Specifically, 72% of the tattoos treated with the laser and RAP achieved 25% or greater fading at 12 weeks; when treated by laser alone, only 40% of tattoos faded by 25% or more. There was 75% or greater fading in 19% of the RAP-treated tattoos, something that only happened in 3% of tattoos treated by laser alone.

Furthermore, using RAP plus laser outperformed laser alone following multiple applications. After three sessions, 100% of RAP treated tattoos had 75% or greater fading, versus only 16% of laser-treated tattoos.

Now what

The FDA approval of Soliton's device is a milestone, but there's a lot of work to do. It's still ironing out manufacturing, so a limited launch isn't expected until 2020, and widespread availability isn't planned until 2021.

The device could improve removal, but the company may have to dilute investors to shore up its balance sheet ahead of its commercial launch. There's also no certainty that practitioners will embrace it once it is available.

Therefore, I think Soliton should be viewed as a high-risk stock unsuitable for most investors, at least until we have more insight into its launch plans and financial runway. For now, I'm content to stay on the sidelines and focus on other ideas.

 
This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Soliton, Inc. Stock Quote
Soliton, Inc.
SOLY
$20.26 (0.75%) $0.15

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
633%
 
S&P 500 Returns
140%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/07/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.